Reference
·Supporting source
Thailand AI drug discovery cost-per-validated-target (2026)
USD 250K-650K
Cost-per-validated-target at BIOTEC and Mahidol cost structures in 2026 sits in the USD 250,000-650,000 band, a 60-80% reduction versus the USD 1.5-3.5 million Western big-pharma benchmark for early-stage target identification through hit-confirmation. Compression drivers are cheaper computational labour (Thai PhD computational chemists at USD 35,000-55,000 fully loaded versus USD 180,000-260,000 in Boston or San Francisco), BIOTEC-pooled GPU compute at NSTDA-subsidised rates, and Genome Thailand training-data access at programme rates. The implication: Thailand becomes price-competitive enough that foreign pharma rationally offshores upstream discovery work that would have stayed in-house at higher unit cost.
Figure in context
Cost-per-validated-target at BIOTEC and Mahidol cost structures in 2026 sits in the USD 250,000-650,000 band, a 60-80% reduction versus the USD 1.5-3.5 million Western big-pharma benchmark for early-stage target identification through hit-confirmation. Compression drivers are cheaper computational labour (Thai PhD computational chemists at USD 35,000-55,000 fully loaded versus USD 180,000-260,000 in Boston or San Francisco), BIOTEC-pooled GPU compute at NSTDA-subsidised rates, and Genome Thailand training-data access at programme rates. The implication: Thailand becomes price-competitive enough that foreign pharma rationally offshores upstream discovery work that would have stayed in-house at higher unit cost.
Cost-per-validated-target at BIOTEC and Mahidol cost structures in 2026 sits in the USD 250,000-650,000 band, a 60-80% reduction versus the USD 1.5-3.5 million Western big-pharma benchmark for early-stage target identification through hit-confirmation. Compression drivers are cheaper computational labour (Thai PhD computational chemists at USD 35,000-55,000 fully loaded versus USD 180,000-260,000 in Boston or San Francisco), BIOTEC-pooled GPU compute at NSTDA-subsidised rates, and Genome Thailand training-data access at programme rates. The implication: Thailand becomes price-competitive enough that foreign pharma rationally offshores upstream discovery work that would have stayed in-house at higher unit cost.
Time scope
2026 estimate
Source basis
Supporting source
Interpretation notes
What this tells you
Cost-per-validated-target at BIOTEC and Mahidol cost structures in 2026 sits in the USD 250,000-650,000 band, a 60-80% reduction versus the USD 1.5-3.5 million Western big-pharma benchmark for early-stage target identification through hit-confirmation. Compression drivers are cheaper computational labour (Thai PhD computational chemists at USD 35,000-55,000 fully loaded versus USD 180,000-260,000 in Boston or San Francisco), BIOTEC-pooled GPU compute at NSTDA-subsidised rates, and Genome Thailand training-data access at programme rates. The implication: Thailand becomes price-competitive enough that foreign pharma rationally offshores upstream discovery work that would have stayed in-house at higher unit cost.
What not to do with it
Cost-per-validated-target covers early-stage target identification through hit-confirmation. Excludes downstream lead-optimisation, IND-enabling studies, and clinical-trial costs that scale differently across geographies.
Related figures
Adjacent numbers that add context without drowning the value.
Thailand AI drug discovery and pharma biotech AI-tooling revenue (2024-2028)
NSTDA BIOTEC, Genome Thailand programme, SCB EIC pharma outlook, PReMA industry profile, foreign-partner disclosures
Thailand AI drug discovery activity mix (2027 estimate)
NSTDA BIOTEC; Siriraj Centre of Research Excellence; SCB EIC pharma outlook; PReMA industry profile
Genome Thailand WGS cohort buildout (2024-2027)
Ministry of Higher Education, Science, Research and Innovation; NSTDA Genome Thailand programme; NSTDA annual report
Thailand AI drug discovery operator concentration (2027 estimate)
NSTDA BIOTEC; Mahidol Centre for Computational Drug Discovery; Chulalongkorn Health Innovation Hub; Siriraj Centre of Research Excellence; foreign-partner disclosures
BOI Section 8 AI compute credit (effective Q1 2026)
Thailand Board of Investment Section 8 R&D announcement
Foreign-pharma Thailand clinical-trial spend (2025-2027)
AstraZeneca Thailand R&D briefings; Roche Thailand personalised healthcare disclosures; SCB EIC pharma outlook
Report context
Atlas actors in this figure's reports
Profiles covered in the report that cite this number.